Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission

Autor: Landsburg, Daniel J., Falkiewicz, Marissa K., Maly, Joseph, Blum, Kristie A., Howlett, Christina, Feldman, Tatyana, Mato, Anthony R., Hill, Brian T., Li, Shaoying, Medeiros, L. Jeffrey, Torka, Pallawi, Hernandez-Ilizaliturri, Francisco, Reddy, Nishitha M., Singavi, Arun, Fenske, Timothy S., Chavez, Julio C., Kaplan, Jason B., Behdad, Amir, Petrich, Adam M., Bast, Martin A., Vose, Julie M., Olszewski, Adam J., Costa, Cristiana, Lansigan, Frederick, Gerson, James N., Barta, Stefan K., Calzada, Oscar, Cohen, Jonathon B., Lue, Jennifer K., Amengual, Jennifer E., Rivera, Xavier, Persky, Daniel O., Peace, David J., Nathan, Sunita, Cassaday, Ryan D.

PurposePatients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefi

Externí odkaz: http://hdl.handle.net/10150/624897
http://arizona.openrepository.com/arizona/handle/10150/624897

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.

Autor: Honma, Yoshitaka, Swiecicki, Paul L., Rosenberg, Ari Joseph, Hanna, Glenn J., Yang Bruce, Justine, Fujisawa, Takao, Muro, Kei, Kaplan, Jason B., Gorla, Seema Rao, Liu, Shubin, Meng, Changting, Geiger, Jessica Lyn

Publikováno v: Journal of Clinical Oncology; 2024 Supplement, Vol. 42, pTPS148-TPS148, 20p

CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder

Autor: Martinez-Escala, Maria Estela, Kantor, Robert W., Cices, Ahuva, Zhou, Xiaolong A., Kaplan, Jason B., Pro, Barbara, Choi, Jaehyuk, Guitart, Joan

Publikováno v: In Journal of the American Academy of Dermatology September 2017 77(3):489-496

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)

Autor: Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc

Publikováno v: Gordon, L I, Karmali, R, Kaplan, J B, Popat, R, Burris, H A, Ferrari, S, Madan, S, Patel, M R, Gritti, G, El-Sharkawi, D, Chau, F I, Radford, J, de Oteyza, J P, Zinzani, P L, Iyer, S P, Townsend, W, Miao, H, Proscurshim, I, Wang, S, Katyayan, S, Yuan, Y, Zhu, J, Stumpo, K, Shou, Y, Carpio, C & Bosch, F 2023, ' Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659) ', Oncotarget, vol. 14, pp. 57-70 . https://doi.org/10.18632/oncotarget.28352
Scientia

Non-Hodgkin’s lymphoma; SYK inhibitor; Relapsed/refractory Linfoma no Hodgkin; Inhibidor de SYK; Recidivante/refractario Limfoma no Hodgkin; Inhibidor de SYK; Recaiguda/refractària We report an updated analysis from a phase I study of the spleen t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::611458e735d4ba1168636765aa9dcd81
https://ddd.uab.cat/record/271599

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.